KOD - CIK 0001468748
Kodiak Sciences Inc. trades as KOD and has a market capitalization of $1.98 B, making it the #2104 largest US-listed company by market value. This page tracks Kodiak Sciences Inc. through 398 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| SCHEDULE 13G | - | 2026-04-27 |
| Annual report to shareholders | ARS | 2026-04-23 |
| Proxy materials | DEFA14A | 2026-04-22 |
| Proxy statement | DEF 14A | 2026-04-22 |
| Insider trade | 4 | 2026-04-16 |
"Kodiak's momentum has continued to build, highlighted by positive Phase 3 topline results from the GLOW2 study and multiple advancing late-stage and pipeline programs that together reinforce the company's differentiated molecules, platform and long term growth strategy," said Victor Perlroth , M.D., Chief Executive Officer of Kodiak Sciences .
Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p<0.0001).
Phase 3 GLOW2 diabetic retinopathy study – expected timeline to topline data
The largest companies sharing Kodiak Sciences Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Kodiak Sciences Inc. (KOD) has a market capitalization of $1.98 B as of 2026-06-10, ranking #2104 among US-listed companies.
In its latest fiscal year Kodiak Sciences Inc. reported a net loss of $229.97M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.